Articles

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Mayo Clinic, Scottsdale, AZ, USA
Stanford Cancer Institute, Stanford, CA, USA
Incyte Corporation, Wilmington, DE, USA
Princess Margaret Cancer Center, University of Toronto, ON, Canada
Washington University School of Medicine, St. Louis, MO, USA
Frankston Hospital and Department of Clinical Haematology, Monash University, Frankston, Australia
*Oregon Health and Science University, Portland, OR, USA
Saint Agnes Cancer Institute, Baltimore, MD, USA
Weill Cornell Medical Center, New York, NY, USA
University of Michigan, Ann Arbor, MI, USA
Emory University School of Medicine, Atlanta, GA, USA
Birmingham Hematology and Oncology, Birmingham, AL, USA
Duke University Health System, Durham, NC, USA
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA
Cancer Care Centers of South Texas/US Oncology, San Antonio, TX, USA
Columbia Presbyterian Medical Center, New York, NY, USA
Incyte Corporation, Wilmington, DE, USA
Incyte Corporation, Wilmington, DE, USA
Incyte Corporation, Wilmington, DE, USA
Incyte Corporation, Wilmington, DE, USA
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Vol. 100 No. 4 (2015): April, 2015 https://doi.org/10.3324/haematol.2014.115840